Study summary

A TTR-stabilizing pill cut death or heart hospitalization and halved hospitalization rates

ATTRibute-CM trial · 632 people, phase 3 · Published March 2025, Journal of the American College of Cardiology; FDA approved November 2024

35.9%died or were hospitalized for heart causes, vs 50.5% with placebo

What was tested

Acoramidis, a pill that stabilizes the transthyretin protein so it does not break apart into amyloid, against placebo for 30 months.

What they found

Death or first heart-related hospitalization: 35.9% vs 50.5% (hazard ratio 0.64).
Yearly heart-related hospitalizations were halved (0.22 vs 0.45).
Benefits appeared by month 3.

What it means

A second stabilizer option alongside tafamidis.

J Am Coll Cardiol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.